Find the answer quickly, keep its limits attached
This tool retrieves source-specific guidance. It does not choose a patient-specific dose or certify a protocol. Use the quick-answer box to find the relevant source, then confirm the scope and qualifications in its evidence box.
1. Match the actual product and indication
Verify the generic and brand, route, release formulation, combination ingredients and age group. A related product is a candidate to review, not a silent substitute. Read any identity or formulation warning before the dose table. The medication-list form asks for confirmation when matching is uncertain.
Example: an injectable meloxicam product is not an oral-product renal protocol; an intrathecal product must not be treated as an IV formulation.
2. Match the source's renal measure and units
Read whether the source uses Cockcroft-Gault CrCl, measured clearance, GFR, or indexed eGFR. An mL/min value is not automatically interchangeable with mL/min/1.73 m2. Do not silently round a result across a dose boundary.
NIDDK explains that FDA does not favor one estimating equation for every drug. Near a dosing cutoff, the combined creatinine-cystatin C equation may improve decision accuracy. Where an unindexed estimate is appropriate, the BSA conversion is eGFR multiplied by BSA/1.73. Do not apply that conversion to a label that explicitly requires indexed eGFR without a justified reason.
NIDDK: drug dosing in adults with chronic kidney disease. Retrieved November 7, 2026. Retained renal-method reference.
When kidney function is changing, the reported estimate and trend require clinical interpretation; this application does not validate a steady-state assumption for an individual patient.
3. Keep dialysis and dosing context explicit
Identify the dialysis modality and source assumptions. An intermittent-hemodialysis schedule is not a CRRT or peritoneal-dialysis schedule. Check loading versus maintenance instructions, dose timing, supplemental-dose language, indication and monitoring. Drug removal alone does not establish a validated dialysis dose.
When no modality-specific regimen is stored, the answer is a source gap, not a recommendation to use the usual dose.
4. Resolve a discrepancy; do not average it
The label, an institutional protocol and a label mirror serve different roles. A mirror is not a second independent study. Confirm whether the apparent conflict reflects a different indication, organism, formulation, patient population or source revision.
Cephalexin: label ceiling versus an indication-specific UCSF row and linezolid: routine guidance versus a conditional expert option illustrate why the qualifying text remains attached to each source. Specialist or institutional review is needed before adopting a deviating regimen.
5. Record the decision and reassessment plan
For clinical documentation, record the exact product and indication, renal measure with units and time, chosen source and revision, regimen, reason for any source deviation, dialysis assumptions and monitoring/reassessment plan. The source-specific share link preserves the evidence identity; it is not a patient record.
6. Distinguish baseline dosing from treatment-emergent kidney injury
A no-adjustment or pharmacokinetic statement does not cancel a separate toxicity hold or stop instruction. The source-bound briefs keep the renal action, evidence gap and monitoring instruction together, tied to the selected source rather than a blended consensus.
ZYNYZ: baseline PK versus immune nephritis | ZALTRAP: renal dosing versus proteinuria holds
7. Check source integrity before interpreting a discrepancy
A different recommendation may reflect an indication-specific policy, but it can also reflect an internally inconsistent or mixed-product source page. Do not average the doses or infer the missing threshold. The source-integrity log distinguishes excluded mixed-drug/route pages from a correctly scoped summary with an explicit caveat.
Amoxicillin: label, UCSF and UHN instructions kept separate. The reference's renal measure, indication and dialysis assumptions remain controlling. Numeric study boundaries are not automatically clinical severity cutoffs.
NHS Specialist Pharmacy Service: reviewing medicines in renal impairment and NHS Specialist Pharmacy Service: renal information resources. Selected guidance reviewed November 7, 2026; not new product-dose validation.
8. Check three easily missed parts of a renal table
Loading versus maintenance: a reduced maintenance dose does not necessarily reduce the initial dose. Infusion duration: a table may change both the amount and infusion time. Population and method: adult CrCl and pediatric indexed eGFR are not interchangeable merely because their numbers look similar.
These are source-reading checkpoints, not a new dosing rule. Review EMBLAVEO, EXBLIFEP and RECARBRIO with each exact table and its limitations attached.